UCB's orchestra hits dud note: Novartis-partnered Parkinson's asset fails phase 2

UCB’s Novartis-partnered investigational small molecule has failed to improve symptoms of Parkinson’s disease in a phase 2a trial.

The oral asset—dubbed minzasolmin—missed the study’s primary and secondary clinical endpoints, according to a Dec. 16 release.